Vaccitech Newsroom

Newsroom

News & updates

Universal Flu Vaccine Data Presented at NFID 2018

Data on safety and immunogenicity of Vaccitech’s flu vaccine have been presented at the 2018 Annual Conference on Vaccinology Research, run by the National Foundation for Infectious Diseases. The presentation was entitled: A Clinical Study to Determine the Safety and...

Flu vaccine Study Recruits First Participants

The world’s first NHS trial for a universal flu vaccine has recruited its first round of participants, with over 862 people signing up to take part since the trial launched in October 2017. This marks the end of the first phase of the trial, which will open again for...

Vaccitech secures £20m Series A with GV, OSI and Sequoia China

Vaccitech, an Oxford University spinout company developing a universal flu vaccine, among other vaccine-related products, has secured £20m ($27.1m) in Series A financing. The round was co-led by new investors GV, Sequoia China, and existing backer Oxford Sciences...

World-First NHS Trial For Universal Flu Vaccine

The world’s first widespread human testing of a flu vaccine which researchers hope will protect more over 65-year-olds against influenza has begun in the NHS. More than 2,000 people aged 65 and over will be asked to take part in a study supported by the National...

Vaccitech Launch RIVET Study

Vaccitech has engaged with Primary Care Clinical Trial Unit at Oxford University to run a small pilot study entitled RIVET (Re-inventing Influenza vaccine Efficacy Trials) as a precursor to its large phase IIb (INVICTUS) novel influenza vaccine study scheduled to...

Vaccitech Feature in Jenner Institute Autumn 2016 Newsletter

Vaccitech: Spin out kick starts with £10m from Oxford Sciences Innovation Oxford spin out company Vaccitech was launched in May 2016 with a £10m investment from Oxford Sciences Innovation to take a number of vaccines through clinical trials. The company’s most...

OBN Awards 2016: Vaccitech Announced as Finalists

Finalists Announced for OBN Awards 2016 OBN Ltd, the membership organisation supporting the UK’s innovative life sciences companies has announced the finalists of its 8th Annual Awards covering Biotech, Medtech, Synthetic Biology and Digital Health. The OBN Awards...

Dr Steve Chatfield Joins Vaccitech

Vaccitech are delighted to welcome Dr Steve Chatfield following his appointment as a Non-Executive Director with the Company. Steve has worked for more than 35 years in the Biopharmaceutical Industry and the public sector developing and commercialising public health...